Sanofi Buys Vigil In $470 Million Deal For Alzheimer’s TREM2 Drug

Sanofi announced that it had entered into an agreement to acquire Vigil Neuroscience, which is a biotech that was working

UroGen Draws A Split Adcom Panel Vote For Bladder Cancer Drug UGN-102

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Prime Medicine Not Keen On PM359 Advancement Despite Initial Data

CRISPR Scores Win For CTX310 Targeting Cholesterol Patients

Latest news

Sanofi Buys Vigil In $470 Million Deal For Alzheimer’s TREM2 Drug

UroGen Draws A Split Adcom Panel Vote For Bladder Cancer Drug UGN-102

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Prime Medicine Not Keen On PM359 Advancement Despite Initial Data

Top editors picks!

  • Featured, Top 1
  • Latest news, Top editors picks!

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

1

  • Top 1
  • Top editors picks!

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

2

  • Top 2
  • Top editors picks!

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

3

  • Top 3
  • Top editors picks!

Rallybio Scraps Maternal Disorder Candidate RLYB212 Shifting Focus To C5 Inhibitor

4

Other articles

Eli Lilly’s Orforglipron Delivers Efficacy Similar To That Of Injectable GLP-1 Drugs

Despite Primary Endpoint Falling Short, Sanofi Moving Amlitelimb Forward

Mural Oncology Mulls Strategic Alternatives After Latest Failure With IL-2 Candidate

Pfizer Shelves GLP-1 Obesity Drug After Liver Injury In A Patient

Annexon’s C1q Targeting Of Complement System Could Bring About First Treatment For GBS

Bristol-Myers Squibb Puts Its Hat Into The Ring In Targeting 1st-Line Liver Cancer With OPDIVO-Based Regimen

Opthea Runs Out Of Options With Failed Wet-AMD Studies, Reduces Workforce By 65%

To Get Phase 3 Program Going Tempest Seeks Strategic Alternatives For Amezalpat For Liver Cancer

Bristol-Myers Squibb Nabs FDA Regulatory Wins With OPDIVO And Yervoy Combination For CRC

Join Newsletter Today!

Enter your email and get information about the newest posts.
Scroll to Top